Board of Directors
Founder & Chief Executive Officer
Paul Badawi is a Founder and Chief Executive Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI™ Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™ Microstent, and TearCare®.
+ READ MORE
Prior to launching Sight Sciences, Paul led the U.S. healthcare venture capital practice for 3i Group, a global private equity firm. At 3i, Paul managed a portfolio of 12 medical device investments and $120MM invested. He served as a lead investor and board member for Ulthera (acquired by Merz), Xthetix (acquired by J&J), NeoGuide (acquired by Intuitive Surgical), OmniGuide, and Sotera Wireless, and as an observer on the boards of Small Bone Innovations (acquired by Stryker), Zonare (acquired by Mindray), and Transmedics.
Prior to entering the medical device world, Paul worked at the National Institutes of Health as a Research Fellow in the biochemical genetics laboratory of a Nobel Prize-winning scientist credited with cracking the genetic code. Paul received a BS in Biological Sciences from the University of Chicago, an MBA from UCLA, and is a graduate of the Kauffman Fellows Program.
David Badawi, MD
Founder & Chief Technology Officer
Dr. David Badawi is a Founder and Chief Technology Officer of Sight Sciences, Inc. He is a co-inventor of the OMNI™ Surgical System, VISCO360® Viscosurgical System, TRAB®360 Trabeculotomy System, Helix™Microstent, and TearCare®. David leads the company’s application and development of technology towards the treatment of the underlying causes of ophthalmic disease. He also oversees the preclinical and clinical development of each of the company’s products.
+ READ MORE
In addition to building Sight Sciences and helping to bring multiple innovative technologies to the operating room and the ophthalmology clinic, David runs a busy referral and surgical practice in the Chicago suburbs.
David received a BS in Microbiology from the University of Maryland and an MD from Georgetown University. He completed his residency in ophthalmology at the Jules Stein Eye Institute at UCLA and a cornea fellowship at Emory University.
Allegro Investment Fund, L.P.
Staffan Encrantz is the founder and Chairman of Allegro Investment Fund, L.P., a registered Cayman Islands Investment Fund that is managed by Allegro Investment Inc. Located in Menlo Park, CA, Allegro primarily invests in growth stage private companies and supports its portfolio by providing growth capital as well as strategic, operating and financial expertise.
+ READ MORE
Mr. Encrantz has actively led investments in and operation of a variety of companies for over 30 years. He has led the growth and development of both early stage companies and established businesses in a wide variety of fields. Mr. Encrantz is currently Chairman of AnaMar AB, ClosingCorp Inc, Evolve Controls, LLC, Nclear Inc, Alestra Ltd., Koncentra Holding AB and the Koncentra Verkstads AB group. He is also a director of GovX, Inc, Oxymetal SAS and several other companies.
Mr. Encrantz previously worked at ASEA AB, Sweden (now ABB Ltd.), as its deputy General Counsel 1979-1981, as Finance Manager 1981-1984, and during 1984-1990 in Switzerland and the UK as Business Area manager responsible for ABB’s Commodity Trading and Counter Trading group. Prior to this, he worked at Skandia Insurance Co, Sweden as its General Counsel and in private law practice.
Mr. Encrantz holds a law degree (Magna cum Laude) from Uppsala University, Sweden.
Hicks Holdings, LLC
Mack Hicks is currently a Partner of Hicks Holdings, LLC, and has been with the firm since 2007. In addition to his involvement with Hicks Holdings, he served as the Managing Partner of Hicks Cedar Park LLC from 2008 to 2014, which owned and operated the Cedar Park Center and the Texas Stars AHL hockey franchise. Mr. Hicks is also Co-Founder of Golfswing.com, an Internet marketing company focused on online golf instruction.
+ READ MORE
Prior to his involvement with Hicks Holdings, Hicks served as a research analyst at Halcyon Asset Management LLC from 2006 to 2007. Halcyon is a multi-strategy investment firm with $14 billion of AUM, where he was involved in investments in fixed income securities and in public and private equity transactions.
From 2004 to 2006, he served as an analyst in the Financial Sponsors Group of Credit Suisse, an investment banking firm. As an analyst at Credit Suisse, Hicks was involved with several leveraged buyouts, recapitalizations and acquisitions.
Mack received a BA degree from the University of Texas at Austin in 2003, and is currently enrolled in the Owner / President Management Program at Harvard Business School. Hicks is also a member of the North Texas Chapter of YPO. He currently resides in Dallas, Texas, with his wife and daughter.
Scientific Health Development
Carter Meyer has been the Chief Executive Officer of Scientific Health Development (SHD) since its formation in February 2006, and is a general partner of its newest fund. Located in Dallas, Texas, SHD is an investment fund focused on earlier-stage life science companies. Prior to joining SHD, Mr. Meyer was an attorney in private practice for more than 12 years, most recently with the Dallas office of Vinson & Elkins L.L.P.
+ READ MORE
Carter has a BBA in finance from Texas Christian University and a JD from St. Mary’s University School of Law. Mr. Meyer is a director of all SHD portfolio companies.
KCK Medical Technologies
Valeska has been a Managing Director of KCK’s Medical Technologies Investment Group since 2016. KCK is a single-family fund investing in a range of industries in private equity, growth capital, and venture capital, including a focus of growth equity investments in medical technology companies. Valeska is a board member for KCK portfolio companies, including Sight Sciences, Cerapedics, Intuity Medical, and Aerin Medical and is a board observer for Reflexion Medical. Before joining KCK, Valeska held roles in product development, program management, and marketing in medical device companies, including VitalConnect, Acclarent, and NDC.
+ READ MORE
Valeska obtained a BS, MS, and PhD from University of California at Berkeley in Materials Science and Engineering.
Silk Road Medical
Erica Rogers, President and CEO of Silk Road Medical (NASDAQ: SILK), is an experienced leader and entrepreneur in the medical device industry. She most recently led Silk Road Medical through FDA approval of its groundbreaking TCAR devices for the treatment of carotid artery disease, commercial scale-up and initial public offering. Prior to her role at Silk Road Medical, Ms. Rogers was the Chief Operating Officer of Medicines360, a non-profit pharmaceutical company developing drugs and devices for women. She was previously the founder and CEO of Allux Medical, as well as the co-founder of Visiogen, an ophthalmic medical device company acquired by Abbott Medical Optics in 2009. In addition, Ms. Rogers is an advisor to Alydia Health, a company developing solutions for postpartum hemorrhage, and to Venture Investors, one of the leading healthcare venture capital firms based in the mid-western United States.
+ READ MORE
Erica holds five issued and 15 pending U.S. patents in medical devices and nanotechnology.